artenimol has been researched along with gefitinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kong, L; Li, Y; Liu, H; Liu, X; Wang, LL; Yuan, F; Zhang, L; Zhang, Y; Zuo, Z | 1 |
| Das, D; Hong, J | 1 |
| Cao, Y; Jiang, AY; Jiang, XF; Jin, H; Wang, H; Wu, Y | 1 |
| Lai, XY; Shi, YM; Zhou, MM | 1 |
1 review(s) available for artenimol and gefitinib
| Article | Year |
|---|---|
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
3 other study(ies) available for artenimol and gefitinib
| Article | Year |
|---|---|
Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Artemisinins; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
Topics: Apoptosis; Artemisinins; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin B1; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |